HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.
To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and BP1001-A, a drug product modification of prexigebersen, has been cleared by the FDA and Phase 1 studies in solid tumors will commence in 2022. The Company’s second product BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, in 2022 or first quarter 2023.
For more information, please visit the Company’s website at http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
Amazfit Smart Wearables Require No Additional SubscriptionMILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand…
Amazfit Smart Wearables Require No Additional SubscriptionMILPITAS, Calif.--(BUSINESS WIRE)--#DiscoverAmazing--Amazfit, a leading global smart wearable brand…
Dual-System Agreement Highlights Transition Towards Advanced Bedside NavigationTYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or…
NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)…
Cincinnati Children’s Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their…
Innovate GBM Community Innovate GBM’s Community Members gather at the NASDAQ Closing Bell Ceremony—united in…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
